Theravance Biopharma (TBPH) Receivables - Other (2013 - 2026)

Theravance Biopharma (TBPH) has reported Receivables - Other for 14 consecutive years, with $15.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other rose 1.5% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $15.6 million (up 1.5% YoY), while the FY2025 annual figure was $45.5 million, up 146.96% from the prior year.
• Receivables - Other slipped to $15.6 million in Q1 2026 per TBPH's latest filing, from $45.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $45.5 million in Q4 2025 and bottomed at $12.3 million in Q1 2023.
• Historically, Receivables - Other has averaged $19.0 million across 5 years, with a median of $16.8 million in 2022.
• Annual changes were most pronounced in 2023 — Receivables - Other tumbled 65.49% — and 2025, when it jumped 146.96%.
• Theravance Biopharma's Receivables - Other stood at $16.8 million in 2022, then advanced by 4.1% to $17.5 million in 2023, then advanced by 5.53% to $18.4 million in 2024, then jumped by 146.96% to $45.5 million in 2025, then sank by 65.78% to $15.6 million in 2026.
• Business Quant data shows TBPH's Receivables - Other at $15.6 million in Q1 2026, $45.5 million in Q4 2025, and $18.3 million in Q3 2025.